J Diabetes Metab Disord. 2026 Feb 24;25(1):81. doi: 10.1007/s40200-026-01908-5. eCollection 2026 Jun.
ABSTRACT
A major consequence of diabetes mellitus (DM) is a diabetic cardiomyopathy (DC). It is a clinical confusion that is identified when individuals with DM develop ventricular dysfunction without having coronary artery disease, heart disease or high blood pressure. It is marked by early diastolic dysfunction and late systolic heart failure. Although mesenchymal stem cell-conditioned media (MSC-CM) have demonstrated promise as therapies for a variety of illnesses, their therapeutic use is hampered by a lack of clinical studies and thorough knowledge of the underlying process. By focusing on oxidative stress, inflammation, and heart failure brought on by hyperglycaemia, this study investigates the positive effect and the possible mechanism by which MSCs-CM alleviate DC in a streptozotocin-induced diabetic rat model by two different delivery routes. 50 male albino rats were randomly assigned to 5 groups, each with 10 subjects, following the induction of diabetes. Amaryl was given to one group as part of their regular diabetes treatment. Every day, 0.5 mL of stem cell-conditioned media was given intravenously (IV) through the tail vein to a different group known as the DC group. Furthermore, 0.5 mL of stem cell-conditioned media was locally administered to a different DC group, going straight into the pancreas. For comparison, a typical control group was also included. All treatments continued for 28 days. Results showed significant alterations in serum glucose, insulin, HbA1c, lipid profile, and cardiac function parameters (atrial natriuretic peptide, troponin I, aspartate aminotransferase, creatine kinase MB) in DC group compare with controls. Treatment by Amaryl® and MSCs-CM demonstrated significant improvements in these parameters, indicating potential therapeutic benefits in diabetic cardiomyopathy. Furthermore, DC exhibited elevate levels of inflammatory markers (CRP, TNFα, IL-6 and Selectin), oxidative stress indicators (malondialdehyde, catalase, superoxide dismutase, and reduced glutathione), and cardiac injury biomarkers (erythropoietin, nuclear respiratory factor 2, vascular endothelial growth factor, and iNOS), which were attenuated by Amaryl® and MSCs-CM treatment (Fig. 3). These findings suggest the antioxidative, anti-inflammatory, and cardioprotective effects of MSCs-CM in diabetic cardiomyopathy highlighting their potential as a viable novel strategy for diabetic cardiovascular complications.
PMID:41757379 | PMC:PMC12932770 | DOI:10.1007/s40200-026-01908-5